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Abstract
Background: The serotonin (5-hydroxytryptamin; 5-HT) system has a central role in the circuitry of cognition and
emotions. Multiple lines of evidence suggest that genetic variation in the serotonin transporter gene (SLC6A4; 5-
HTT) is associated with schizophrenia and suicidal behavior. In this study, we wanted to elucidate whether SLC6A4
variations is involved in attempted suicide among patients with schizophrenia in a Scandinavian case–control
sample.
Methods: Patients diagnosed with schizophrenia from three Scandinavian samples were assessed for presence or
absence of suicide attempts, based on record reviews and interview data. Seven SLC6A4 single nucleotide
polymorphisms (SNPs) were genotyped in 837 schizophrenia patients and 1,473 control individuals. Association
analyses and statistical evaluations were performed with the program UNPHASED (version 3.0.9).
Results: We observed an allele association between the SNP rs16965628, located in intron one of SLC6A4, and
attempted suicide (adjusted p-value 0.01), among patients with schizophrenia. No association was found to a
diagnosis of schizophrenia, when patients were compared to healthy control individuals.
Conclusion: The gene SLC6A4 appears to be involved in suicidal ideation among patients with schizophrenia.
Independent replication is needed before more firm conclusions can be drawn.
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Background
The lifetime risk of committing suicide among patients
with schizophrenia is approximately 5% [1,2]. Also
attempted suicide is common, with estimates ranging
from 20% to 40% [3]. The heritable component of
suicide attempt is partly related to psychiatric disorders
but also partly independent of them [4-6].
The serotonin (5-hydroxytryptamin; 5-HT) system has
a central role in the circuitry of cognition and emotions
and exerts significant effects on anxiety, mood, impulsiv-
ity, sleep, ingestive behavior, reward systems, and psych-
osis [7]. Pharmacological agents targeting central 5-HT
system has substantial effects on emotional behaviors
[8-10]. Moreover, several reports imply that 5-HT may
be involved in pathophysiological events associated with
suicide [11-15]. In fact, postmortem examination of sui-
cide victims shows significantly lower serotonin trans-
porter binding in the prefrontal cortex [16].
Epidemiological and genetic studies indicate that
there is a genetic component to suicidal behavior [17].
For example, a single nucleotide polymorphism (SNP)
(rs1800532, A218C) in the tryptophan hydroxylase 1 gene
(TPH1), which encodes a rate-limiting enzyme involved
in the development of 5-HT, was previously found to be
associated with suicide or suicidal attempt [18,19]. The
same SNP was also investigated by us in the Scandinavian
case–control material used in the present study [20].
However, no association was detected between TPH1
A218C and suicide attempt among the patients, although
an association was found to schizophrenia.
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Another gene in the serotonin system, reported several
times to be involved in the risk of attempting suicide, is
the serotonin transporter gene (SLC6A4 or 5-HTT)
[11,12,19,21]. The human SLC6A4 gene (Figure 1),
located on chromosome 17q11.2, is about 39,500 base
pairs long and contains 14 exons, of which exons 1a and
1b are alternatively transcribed. The gene encodes a
membrane protein that plays a major role in the regula-
tion of synaptic serotonin concentrations by recycling
serotonin from the synaptic cleft.
Results from studies of 5-HTT knockout mouse have
provided important clues regarding downstream effects
of altered 5-HT function on behavior and the develop-
ment of the brain, such as regulation of cell prolifera-
tion, migration and differentiation of neuronal tissue
[22,23]. Interestingly, early alterations in 5-HT availabil-
ity during the development of the 5-HT system might
impact the distribution and density of specific 5-HT
receptors, thereby altering the postsynaptic effects of
5-HT on target neurons and the reactivity of these
neurons to specific stimuli [24].
In recent years, five genome-wide studies analyzing
suicidal behavior in patients with bipolar disorder, alco-
holism and major depression identified candidate regions
on chromosome 2p11-12, 2p25 and 6q25-26 [6,25-29].
As far as we know, no genes associated with suicidal
behavior have been reported in these regions yet. Neither
are we aware of any genome wide studies analyzing sui-
cidal behavior in patients with schizophrenia.
In the present study, we wanted to further explore the
possible involvement of the serotonin system in suicide
among patients with schizophrenia, by analyzing genetic
variations in the SLC6A4 gene using a Scandinavian
case–control sample. Scandinavian countries are gener-
ally considered to be well suited for genetic studies, as
the populations are ethnically homogeneous and only re-
cently have been subject to non-Caucasian immigration.
Seven SNPs located in the SLC6A4 gene (Figure 1), were
selected and genotyped in 837 patients suffering from
schizophrenia and related disorders, of which 738 had
information on suicidal behavior, and in 1,473 control
individuals.
Methods
Clinical samples
The clinical samples originate from the Scandinavian
Collaboration on Psychiatric Etiology (SCOPE) and were
collected in Denmark (DK), Norway (NO), and Sweden
(SE). Affected individuals were diagnosed according to
ICD-10 (DK) or DSM-III-R/DSM-IV (NO and SE). All
individuals were born in Scandinavia and of Caucasian
origin, and the vast majority had two Scandinavian born
parents. Detailed description of the samples was
reported earlier [20,30-33]. The total sample set included
837 patients, of which 734 were diagnosed with schizo-
phrenia, 87 with schizoaffective disorder and 16 with
schizophreniform disorder, and 1473 control individuals
(Table 1). Patients (N = 738) were assessed for presence
or absence of suicide attempts based on record reviews
(DK, SE) and interview data (NO, SE). Any previous
self-harm in combination with suicidal ideation, docu-
mented or reported, was regarded as a suicide attempt.
For the present analyses, subjects were divided into
those who had made at least one suicide attempt and
those who had not attempted suicide. The Danish Scien-
tific Committees, the Danish Data Protection Agency,
the Norwegian Scientific-Ethical Committees, the Nor-
wegian Data Protection Agency, the Ethical Committee
of the Karolinska Hospital, the Stockholm Regional Eth-
ical Committee and the Swedish Data Inspection
Board all approved the study. All participants had
given informed consent prior to inclusion in the study.
SNP Genotyping
Seven SNPs in the SLC6A4 gene, previously reported
to be associated with schizophrenia, were analyzed.
Genomic DNA was extracted from whole blood
samples, and the polymorphisms were genotyped at
the SNP Technology Platform in Uppsala, Sweden
(www.genotyping.se), using the Illumina BeadStation
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Figure 1 Genomic structure of the SLC6A4 gene. Exons (1a–14) are represented by filled boxes and untranslated regions are represented with
open boxes. The 5’-UTR is indicated with a dashed line. The SNPs in the figure was included in present study. The 5-HTTLPR locus marked with
grey color, was not included in the present association study.
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500GX and the 1536-plex Illumina Golden Gate assay
(Illumina, Inc., San Diego, CA). The sample success rate
was on average 99.7% for the genotyped SNPs and the
reproducibility of the genotyping was 100% according
to duplicate analysis of 2.6% of the genotypes.
Statistical analyses
Hardy–Weinberg (HW) equilibrium was tested in the
control samples using Fisher’s exact test as implemented
in PEDSTATS [34]. Accounting for the number of tested
markers, no SNP deviated significantly from HW equi-
librium. Linkage disequlibrium (D’ and R2) between SNP
pairs, and haplotype block structure [35] were deter-
mined with Haploview 4.0 [36] (Additional file 1: Figure
S1). The fixation index (FST) was calculated for each
SNP separately, and all loci combined, in the control
sample with FSTAT, grouping controls by country of ori-
gin. No evidence of population stratification was evident
from the data: the fixation index for all combined loci
was 0.003 (0.001-0.005) (95% bootstrap confidence
interval).
Association analysis comparing allele and genotype
frequencies between suicide attempters and non-
attempters within the patient group and between
affected individuals and controls were performed with
UNPHASED (version 3.0.9) [37,38]. To account for pos-
sible population stratification and the effect of sex, we
included country of origin and sex as confounding fac-
tors in the analyses. To examine whether genetic
associations were homogenous, we carried out separate
analyses testing if country and gender modified the asso-
ciation. Correction for multiple testing was done by per-
mutation tests (n = 1000).
Results
Out of the seven markers tested, only rs16965628
located in the SLC6A4 gene, showed significant associ-
ation to suicide attempt (P-value for allele association =
0.00092) and the result remained significant also after
correction for multiple testing (P-value = 0.01) (Table 2).
The minor allele C was underrepresented among
patients with records of suicidal behavior.
We also performed genotype association analyses.
However, due to the low frequency of the minor allele of
rs16965628 (0.05) only one individual was CC homozy-
gous, and consequently the same association signal was
captured with the allele and the genotype test. We did
not find any evidence of heterogeneity in the association
signal between the three countries, nor between male
and female patients for this marker (P-value = 0.75 and
0.17, for country and gender as modifiers, respectively).
In other words, all countries and both genders contribu-
ted to the observed association between rs16965628 and
suicidal behavior.
For completeness, the allele and genotype frequencies
of the seven polymorphisms in patients with suicidal be-
havior were also contrasted against the frequencies in
healthy controls. The results were similar to the com-
parison within the patient group, and the rs16965628 C-
allele was significantly lower among individuals with sui-
cidal behavior than in the controls (p-value = 0.01 after
correction for multiple testing, data not shown).
Since genetic variants in the SLC6A4 were previously
found to be associated with schizophrenia in other sam-
ple sets [39-44], we analyzed the association between the
seven SNPs and schizophrenia in the Scandinavian
case–control sample. Two SNPs were weakly associated
with the disease (Table 3), but after correction for mul-
tiple testing no association was statistically significant
(P-value > 0.10).
We analyzed linkage disequilibrium (LD) between the
polymorphisms and found two blocks. All markers, except
rs16965628, were located in the observed LD blocks (Add-
itional file 1: Figure S1). Haplotype association analyzes for
the two blocks, with respect to suicidal attempt and schizo-
phrenia susceptibility, were performed with UNPHASED.
The haplotype and single marker analyzes gave similar
results, i.e. there were no significant haplotype association
with neither phenotype (p> 0.106, data not shown).
Discussion
In the present study we found an association between
the SLC6A4 rs16965628 polymorphism and attempted
Table 1 Characteristics of Danish (DK), Norwegian (NO),
and Swedish (SE) samples analyzed for association
between serotonin transporter gene (SLC6A4)
polymorphisms and schizophrenia and suicide attempt
among affected (cases) and control individuals
Country Characteristics Cases Controls
DK N 420 1004
Gender (% women) 42.6 41.5
Age 43.9 ± 12.3 43.2 ± 11.8
Age of onset 27.2 ± 8.9
No of suicide attempters 153
NO N 162 177
Gender (% women) 46.3 55.5
Age 37.2 ± 10.7 38.7 ± 10.3
Age of onset 27.6 ± 8.7
No of suicide attempters 42
SE N 255 292
Gender (% women) 37.2 37.7
Age 54.1 ± 15.2 50.3 ± 10.1
Age of onset 24.6 ± 6.9
No of suicide attempters 95
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suicide among patients with schizophrenia (P-value =
0.00092 and global P-value = 0.01). The odds ratio was
0.39, indicating that the presence of the minor C-allele
protects against suicidal behavior. The rs16965628 poly-
morphism is located in the first intron of the SLC6A4
gene, approximately 9 kb downstream of promoter re-
gion. The most studied polymorphisms in the SLC6A4
gene are a 44-base pair insertion–deletion in the pro-
moter region, generating the major L (LA and LG) and
S-alleles, and a 17-bp variable number of tandem repeats
(VNTR) in the second intron [45]. During the years con-
flicting results have been reported regarding genetic var-
iants in the SLC6A4 gene and suicidal ideation [46]. The
ambiguous results from different studies possibly reflect
insufficient sample sizes to obtain adequate statistical
power, and heterogeneity between populations [47].
However, the two latest of three meta-analyses report as-
sociation between SLC6A4 variants and suicidal behavior
[11,12,21]. In the latest and largest meta-analysis,
including 39 different association studies (covering all
published studies up to 2006), a significant association
was found between 5-HTTLPR and suicide attempts/
suicide. The L-allele was underrepresented among indi-
viduals with suicidal behavior (odds ratio was 0.88), sug-
gesting that the investigated gene variant had a
protective effect against suicide [11].
The mechanism behind this association is unknown,
but the 5-HTTLPR polymorphism appears to affect
SLC6A4 gene expression. That is, the transcription of
the SLC6A4 gene is lower in the presence of the S-allele
as compared to the L or the LA-alleles [48,49]. As men-
tioned in the introduction, postmortem examination of
suicide victims shows significantly lower serotonin trans-
porter binding in the prefrontal cortex [16]. Thus it is
possible that the protective effect of the L-allele is the
result of elevated expression of the serotonin transporter
protein, leading to an overall increase in serotonin trans-
porter binding.
Table 3 Serotonin transporter (SLC6A4) single nucleotide polymorphisms (SNPs) investigated in patients with
schizophrenia and control subjects
SNP Base MAF Genotype counts (schizophrenia/control) Allele association Genotype association
Allele 1 Allele 2 OR OR OR
(1/2) Homozyogotes Heterozygotes Homozygotes p-value 2 vs 1 p-value 12 vs 11 22 vs 11
Rs1042173 A/C 0.46 223/410 402/770 207/291 0.083 1.11 0.022 0.93 1.27
Rs4583306 A/G 0.42 276/475 410/755 173/237 0.020 1.16 0.020 1.04 1.40
Rs140700 C/T 0.09 689/1233 140/221 2/10 0.435 1.09 0.171 1.17 0.39
Rs2020942 C/T 0.14 313/528 390/714 128/228 0.359 0.94 0.518 0.90 0.91
Rs12150214 G/C 0.18 595/982 219/438 21/46 0.123 0.88 0.282 0.86 0.83
Rs4251417 C/T 0.09 673/1204 148/257 9/7 0.214 1.14 0.123 1.07 2.78
Rs16965628 G/C 0.06 753/1310 77/152 1/9 0.192 0.83 0.125 0.91 0.19
The table shows nominal allele and genotype association results with gender and country as covariates.
Nominal allele and genotype association results are reported with gender and country as covariates. MAF, minor allele frequencies in control individuals (allele 2
in the table).
Nominally significant; after correction for multiple testing using permutation test, all P- values > 0.10.
Table 2 Serotonin transporter (SLC6A4) single nucleotide polymorphisms (SNPs) investigated in suicidal attempters
(SA) and non-suicidal (No SA) attempters with a schizophrenia diagnosis
SNP SNP
localization
Position MAF Base Genotype counts Allele association Genotype association
(SA/No SA) OR OR OR
(no of bases) (1/2) 1 1 1 2 2 2 P-value 2 vs 1 P-value 12 vs 11 22 vs 11
Rs1042173 3'-UTR 28525011 0.47 A/C 70/125 144/195 75/104 0.218 1.14 0.27 1.34 1.29
Rs4583306 Intron 8 28538715 13704 0.03 A/G 77/134 150/201 60/88 0.335 1.11 0.29 1.33 1.20
Rs140700 Intron 5 28543389 4674 0.08 C/T 243/348 43/79 2/0 0.560 0.89 0.11 0.80 2.26E9
Rs2020942 Intron 2 28546914 3525 0.39 C/T 108/157 135/201 44/68 0.777 0.97 0.94 0.99 0.93
Rs12150214 Intron 1 28550888 3974 0.17 G/C 213/301 67/117 10/8 0.735 0.95 0.23 0.81 1.72
Rs4251417 Intron 1 28551858 970 0.10 C/T 227/347 55/77 4/1 0.338 1.19 0.18 1.07 6.26
Rs16965628 Intron 1 28555425 3567 0.05 G/C 272/374 15/51 0/1 0.0009 (0.01) 0.39 0.004 (0.02) 0.40 3.92E-5
The table shows nominal allele and genotype association results with gender and country as covariates.
Chromosomal position, minor allele frequency (MAF), SNP-alleles (Base), genotype counts, P-values and odds ratios (OR) for allele and genotype association for the
seven SNP markers are presented in the table. Global significant P-values are shown in parenthesis.
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The relative abundance of allele transcripts of the
serotonin transporter gene in human cell lines from
HapMap CEPH trios, confirm the effects of 5-HTTLPR
variation on the transcription of the SLC6A4 gene [50].
However, in these cell lines variation in the rs16965628
SNP was associated with considerably more transcrip-
tional variation than the 5-HTTLPR polymorphism, and
the rs16965628 C-allele was linked with increased tran-
scription (the mean allele G/C transcript ratio was 0.47)
[50]. Thus we speculate that the decreased frequency of
suicidal behavior among schizophrenic patients that car-
ried the rs16965628 C-allele, observed in this study, may
have been caused by increased transcription of the
SLC6A4 gene and a corresponding increase in serotonin
transporter binding.
The gene SLC6A4 has frequently been implicated in
psychiatric disorders [51]. Meta-analyses have reported
association between 5-HTTLPR S-variant - and some-
times also the 17-bp VNTR in intron 2 polymorphism -
and bipolar disorder [52-55], co-morbid bipolar disorder
and tobacco use disorder [56], alcohol dependence
[57,58], major depression [59,60], antidepressant-induced
mania [61,62], a modulation effect of 5-HTTLPR on
stress and depression [63], however highly discussed
[64], and anxiety-related traits [65-67], almost all disor-
ders with elevated rates of suicide or suicide attempts.
Almost all of the above mentioned disorders show ele-
vated rates of suicide or suicide attempts. In schizophre-
nia, the 5-HTTLPR and 17-bp VNTR in intron 2
polymorphisms have been associated with the disorder in
individual studies and the 17-bp VNTR also in several
meta-analyses [68-70]. However, the latest update in the
SzGene database (www.szgene.org) indicates lack of
overall allele association. In previous studies, 5-HTTLPR
and schizophrenia was investigated by us using Swedish
case–control samples, partly overlapping with the
present. The results indicated that alleles within the
gene were associated with age of onset [71] and disease
[44]. Other researchers reported that a haplotype, includ-
ing markers 5-HTTLPR and rs16965628, was associated
with obsessive compulsive disorder [72]. Furthermore,
rs16965628 was found to modulate task-related activa-
tion in ventral prefrontal cortex in patients with post-
traumatic stress disorder [73]. Patients with obsessive
compulsive disorder and posttraumatic stress disorder
are known to have an elevated risk of committing suicide
[74,75].
In the present study, we did not find any significant
association between genetic variants in SLC6A4 and
schizophrenia although an association was found to sui-
cide attempt. This may seem contradictive but previous
epidemiological studies including monozygotic and di-
zygotic twins showed an elevated risk of attempting sui-
cide even after controlling for psychiatric disorders,
indicating that genetic factors independent of psychiatric
disorders affect the risk of suicide attempt [4,5]. Thus
our results do not support that the investigated SNPs
are associated with a substantial increase in the disease
risk in the Scandinavian population. However, even
though our sample size was large, it does not have the
power to unambiguously detect weak signals, and thus a
true association with an odds ratio below 1.2 cannot be
ruled out [76].
Conclusions
The present results provide support for an association
between a relatively uncommon SLC6A4 polymorphism
and suicidal behavior among schizophrenic patients of
Scandinavian origin. As the marker was not associated
with the disease, the decreased risk for suicidal behavior
appears to be unlinked to that of schizophrenia suscep-
tibility. Although the estimated effect of the rs1695628
C-allele was substantial, its low frequency suggests that
the potential contribution to variation in suicidal be-
havior in the population would be limited. Further
studies in independent samples are needed to establish
a link between rs1695628 and suicidal behavior in the
Scandinavian and other populations.
Additional file
Additional file 1: Figure S1. Linkage disequilibrium (LD) structure in
the three Scandinavian control samples of seven serotonin transporter
gene (SLC6A4) single nucleotide polymorphisms. Haplotype block
structure (outlined), D’ (numbers, 100 not printed) and r2 (shadings) are
given. The figure shows pair-wise LD among the seven SLC6A4 SNPs, as
calculated by the Haploview 4.0 software. High r2 values with strong
linkage disequilibrium are indicated by dark color. Gray and white colors
indicate weak linkages with low r2 values. The genetic positions of the
SNPs in the SLC6A4 gene are indicated in the white bar above the LD-
plot.
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